



Dr. Arzu Güneş Granberg

Çalıştığı Yer ve Görevi: Medical Products Agency (Läkemedelsverket, İsveç), Klinik Psikiyatri Etki ve Güvenlik denetleyicisi

Branşı: Klinik farmakoloji

İlgilendiği Alanlar: Klinik psikofarmakoloji, Farmakovijilans, İlaç geliştirme ve denetlenmesi, Klinik farmakogenetik.

Görev Aldığı Dernekler: İsveç Hekimler Derneği, Türk Farmakoloji Derneği

Daha Önce Çalıştığı Yerler:

1. Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Farmakoloji Anabilim Dalı, Ankara, Türkiye
2. Uppsala Üniversitesi, Tıp Fakültesi, Tıbbi Bilimler Enstitüsü, Klinik Farmakoloji, Uppsala, İsveç
3. AstraZeneca R&D, Early Clinical Development, Mölndal, İsveç
4. Medical Products Agency (Läkemedelsverket), Uppsala, İsveç

Araştırma-Bildiri ve Kitapları Hakkında:

Makaleler

Gunes A, Ceylan A, Sarioglu Y, Stefek M, Bauer V, Karasu C; The Antioxidants in Diabetes-induced Complications (ADIC) Study Group. Reactive oxygen species mediate abnormal contractile response to sympathetic nerve stimulation and noradrenaline in the vas deferens of chronically diabetic rats: effects of in vivo treatment with antioxidants. *Fundamental & Clinical Pharmacology*, 2005; Feb 19(1):73-79.

[Ulus NN, Ozbey G, Tandoğan B, Gunes A, Durakoglugil DB, Karasu C, Uluoglu C, Zengil H.](#) Circadian variations in the activities of 6-phosphogluconate dehydrogenase and glucose-6-phosphate dehydrogenase in the liver of control and streptozotocin-induced diabetic rats. *Chronobiology International*, 2005; 22(4): 667-77.

Gunes A, Coskun U, Boruban C, Gunel N, Babaoglu MO, Sencan O, Bozkurt A, Rane A, Hassan M, Zengil H, Yasar U. Inhibitory effect of 5-fluorouracil on CYP2C9 activity. *Basic & Clinical Pharmacology & Toxicology*, 2006; 98:197-200.

Gunes A, Scordo MG, Jaanson P, Dahl M-L. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side-effects in perphenazine treated schizophrenic patients. *Psychopharmacology*, 2007; Mar 190(4):479-84.

Melkersson KI, Scordo MG, Gunes A, Dahl M-L. Impact of CYP1A2 and CYP2D6 genetic polymorphisms on drug metabolism and on insulin – and lipid elevations and insulin resistance in patients on treatment with clozapine. *Journal of Clinical Psychiatry*, 2007; May 68(5):697-704.

Gunes A, Bilir E, Zengil H, Babaoglu MO, Bozkurt A, Yasar U. Inhibitory Effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. *Basic & Clinical Pharmacology & Toxicology*, 2007; June 100(6), 383-6.

Uluoglu C, Durakoglugil DB, Karasu C, Ozbey G, Gunes A, Zengil H. The effect of experimental diabetes on the temporal pattern of the vasodilator responses to acetylcholine and isoprenaline in the rat aorta. *Chronobiology International*, 2007; 24(6), 1081-94.

Uluoglu C, Cimen B, Ozbey G, Karasu C, Durakoglugil DB, Gunes A, Turkozkan N, Zengil H. The effect of experimental diabetes on the circadian pattern of adenosine deaminase and myeloperoxidase activities in rat liver. *Gen Physiol Biophys*. 2008 Mar;27(1):25-31.

Gunes A, Dahl M-L, Spina E, Scordo MG. Further evidence for association between 5-HT_{2C} receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. *European Journal of Clinical Pharmacology*, 2008; 64: 477-482.

Gunes A, Spina E, Dahl ML, Scordo MG. ABCB1 Polymorphisms Influence Steady-State Plasma Levels of 9-Hydroxyrisperidone and Risperidone Active Moiety. *Ther Drug Monit*. 2008; 30:5, 628-633.

Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl M-L. The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response: An Analysis from the PRINC (Plavix Response in Coronary Intervention) Trial. *JACC: Cardiovascular Interventions*, 2008: Dec 1(6): 620-627.

Patrick Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl M-L. The Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of Clopidogrel: The PRINC (Plavix Response in Coronary Intervention) Trial. *JACC: Cardiovascular Interventions*, 2008: Dec 1(6): 612-619.

Gunes A, Melkersson KI, Scordo MG, Dahl ML. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. *J Clin Psychopharmacol*. 2009: Feb; 29(1):65-8.

Gunes A, Ozbey G, Vural EH, Uluoglu C, Scordo GS, Zengil H, Dahl ML. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. *Pharmacogenomics*. 2009: May; 10(5):769-78.
Mao M, Matimba A, Scordo MG, Gunes A, Zengil H, Yasui-Furukori N, Masimirembwa C, Dahl ML. Flavin-containing monooxygenase 3 polymorphisms in 13 ethnic populations from Europe, East Asia and sub-Saharan Africa: frequency and linkage analysis. *Pharmacogenomics*. 2009 Sep;10(9):1447-55.

Melkersson KI, Gunes A, Dahl ML. Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine- and olanzapine-treated patients *Hum Psychopharmacol*. 2010 Jun; 25(4):347-52.

Gokalp O, Gunes A, Cam H, Cura E, Aydin O, Tamer MN, Scordo MG, Dahl M-L. Mild hypoglycaemic attacks induced by oral antidiabetics in routine clinical setting related to CYP2C9 and CYP2C8 polymorphisms. *Eur J Clin Pharmacol*. 2011 Dec; 67(12):1223-9.

Hedenmalm K, Granberg AG, Dahl ML. Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population- based case-control study including 1st and 2nd degree relatives. *Eur J Clin Pharmacol*. 2015 Jan; 71(1):117-24.

Derlemeler:

Ozdemir V, Gunes A, Dahl M-L, Scordo MG, Williams-Jones B, Someya T. Genomic data integration from pharmacokinetic pathways and drug targets: could endogenous substrates of drug metabolizing enzymes influence constitutive physiology and drug target responsiveness? *Pharmacogenomics*, 2006: Dec 7(8):1199-210.

Gunes A, Dahl M-L. Variation in cytochrome P450 1A2 (CYP1A2) activity: Influence of environmental factors and genetic polymorphisms, *Pharmacogenomics*, 2008: May 9(5):625-37.

Liou G, El-Remessy A, Ibrahim A, Caldwell R, Khalifa Y, Gunes A, Nussbaum J. Cannabidiol As a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development. *Curr Pharmacogenomics Person Med*. 2009 Sep; 7(3):215-222.

Gunes A, Dahl M-L. Implications of inter-individual differences in clopidogrel metabolism with focus on pharmacogenetics. *Pharmaceuticals* 2010, 3(4), 782-794.